SCHEMBL25259697

SCHEMBL25259697

O=C(O)N1OCC[C@H]1c1cnccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.35
NAPRT Q6XQN6 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
KCNK3 O14649 1/20 0.34
CYP2C9 P11712 1/20 0.33
EPHX2 P34913 1/20 0.33
SCD5 Q86SK9 1/20 0.32
RIPK1 Q13546 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
TSHR P16473 1/20 0.31
MC4R P32245 1/20 0.31
ADRA1A P35348 1/20 0.31
MC3R P41968 1/20 0.31
SMYD3 Q9H7B4 1/20 0.31
GRM5 P41594 3/20 0.31
MAPT P10636 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25816648 0.81 DYRK1A (0.39) KDM4EKCNK3RIPK1SMYD3
SCHEMBL30547544 0.80 GPR119 (0.46) KDM4EKCNK3
SCHEMBL25816509 0.80 GPR119 (0.46) KDM4EKCNK3
SCHEMBL20580062 0.79 ALDH1A1 (0.32) KDM4ERIPK1MAPTALDH1A1HSD17B10
SCHEMBL31196458 0.79 RIPK1 (0.35) KDM4EKCNK3RIPK1KMT2ASMN1; SMN2
Trifluoroacetic Acid SCHEMBL25258903 0.78 RIPK1 (0.37) RIPK1
SCHEMBL31200021 0.77 RIPK1 (0.34) KDM4ERIPK1MAPT
SCHEMBL29048303 0.75 DEGS1 (0.36) RIPK1
SCHEMBL25818354 0.75 HRH3 (0.32) KDM4EMAPTALDH1A1
SCHEMBL31205732 0.75 GSK3B (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 KDM4E 2270/4885NAPRT 3006/4885HCAR2 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.